Jérémy Martin's Portfolio
I am a passionate bioinformatician with 2 years of working experience in academy. In one hand, I conduct data anlysis (principaly imaging, transcriptomics, proteomics). In other hand, I built some tools to facilitate data exploration by biologist.
Jan 2021 - Present, Toulouse, FRANCE (31)
Bioinformatician Engineer, I am in charge into analysis of data generated by the laboratory team. To adress the problematics raised by the lab, I design analytical plan using or developping informatic tools.
Jul 2021 - Present
Jan 2021 - Jun 2021
Jun 2020 - Aug 2020, Auzeville, FRANCE (31)
Facultative Internship. Full-remote.
M.Sc. in Bioinformatics and System BiologyClassement: 1 out of 16Taken Courses
Extracurricular Activities
| ||
B.Sc. Hons. in Bioinformatics & System BiologyClassement: 3 out of 17Taken Courses
Extracurricular Activities
| ||
B.Sc. in Biochemistry, Microbiology & Molecular BiologyTaken Courses
| ||
2012-2014 H.N.D. in Medical Laboratory TechnologyTaken Courses
Extracurricular Activities
|
Mast cells (MCs) are tissue-resident immune cells which could be identified as Conjonctive Tissue Mast cells (CTMCs) and Mucosal Mast cells (MMCs). Thank’s to single cell RNA seq approach, we reached to establish transcriptomics profiles of these Mast cells, understanding their functions and tissue-imprintings, with the aim to develop a transcriptomic atlas across organs.
Invited to speak at the Scientific Day organized by Genotoul about heterogeneity in single cell RNA seq data. Presentation about the impact of heterogeneity of scRNA-seq data in a classical analysis pipeline and the importance of taking it into account. Throughout this presentation, I used three different types of datasets, generated by the team, to support my points.
A visual tools for Single Cell RNA seq data. This repo is a draft to the manipulation of RShiny applied to scRNA-seq data and Seurat Object.
Mast cells (MCs) are tissue-resident immune cells which exhibit homeostatic and neuron-associated functions. Here we combined whole-tissue imaging and single cell RNA sequencing datasets to generate a pan-organ analysis of MCs in mice and humans at steady state.
Routine clinical assays, such as conventional immunohistochemistry, often fail to resolve the regional heterogeneity of complex inflammatory skin conditions. Here we introduce MANTIS (Multiplexed Annotated Tissue Imaging System), a flexible analytic pipeline compatible with routine practice, specifically-designed for spatially-resolved immune phenotyping of the skin in experimental or clinical samples. Based on phenotype attribution matrices coupled to α-shape algorithms, MANTIS projects a representative digital immune landscape, while enabling automated detection of major inflammatory clusters and concomitant single-cell data quantification of biomarkers.
The anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase known for its oncogenic potential that is involved in the development of the peripheral and central nervous system. ALK receptor ligands ALKAL1 and ALKAL2 were recently found to promote neuronal differentiation and survival. Here, we show that inflammation or injury enhanced ALKAL2 expression in a subset of TRPV1+ sensory neurons. Notably, ALKAL2 was particularly enriched in both mouse and human peptidergic nociceptors, yet weakly expressed in nonpeptidergic, large-diameter myelinated neurons or in the brain. Using a coculture expression system, we found that nociceptors exposed to ALKAL2 exhibited heightened excitability and neurite outgrowth. Intraplantar CFA or intrathecal infusion of recombinant ALKAL2 led to ALK phosphorylation in the lumbar dorsal horn of the spinal cord. Finally, depletion of ALKAL2 in dorsal root ganglia or blocking ALK with clinically available compounds crizotinib or lorlatinib reversed thermal hyperalgesia and mechanical allodynia induced by inflammation or nerve injury, respectively. Overall, our work uncovers the ALKAL2/ALK signaling axis as a central regulator of nociceptor-induced sensitization. We propose that clinically approved ALK inhibitors used for non–small cell lung cancer and neuroblastomas could be repurposed to treat persistent pain conditions.